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Book Reviews
EAnro'-- Aspects of Cacer
Edited by K. Horwitz, Bethesda: The Endocrine Society
Press, 1993, 256 pp.
This monograph is the first in a series from the Endocrine
Society. Each monograph will include a number of articles
recently published in Endocrine Reviews and focus on a par-
ticular topic. These artiles have all been peer revied and,
as a clever addition, the authors have prepared addenda that
update the articles which appeared originally between 1990
and 1992.
Of the ten chapters in Endorn Aspects of Cancer, the
first six address issues dealing with hormones and breast
cancer. Santen et al. provide a comprehensive summary of
the various modalities used in the endocrine treatment of
breast cancer, Jordan and Murphy focus on anti-oestrogens
and their anti-tumour properties, and Li and Li review the
carcinogenic pro of oestrogens. The next two chapters
address the role of progesterone in cell proliferation (Clarke
and Sutherland) and the potential use of progesterone
antagonists in breast cancer (Horwitz). FinaLy, Klijn et al.
discuss the role of growth factors and their receptors in
breast cancer growth and prognosis with parficular emphasis
on epidermal growth factor.
The emnaining chapters discuss the role of hormones in
ovarian cancer (Rao et al.), dopamine agonists and pituitary
tumours (Bevan et al.), somatostatin and its analogues in the
diagnosis and treatment of a variety of malignances
(Lamberts et al.) and the cellular sources and biological
functions of cytokines (Kurzrock et al.).
Overall these ten chapters are high-quality critical, in-depth
state-of-the-art reviews. The book is well produced and
reasonably priced. My only quibble is with the content mix.
The six chapters on breast cancer fit together beaufifully, but
the remainder are more like four isolated additions.
Clinicians and probably scientists interested in dopamine
agonists and pituitary tumours are unlikely to be equally
interest in breast or ovarian cncer and vice versa. It might
have been better to have concentrated on breast cancer and
produced a smaller monograph entitled 'Endocrine Aspects
of Breast Cancer'.
S.M. Shalet
Cardiac Toxkity after Treatmet for C Ca r
Edited by J.T. Bricker, D.M. Green & GJ. D'Angio, New
York: Wiley-Liss, 1993, 133 pp.
As the treatment of children with cancer has improved,
concern about possible late effects has also increased. Over
half the children diagnosed with cancer will now survive
more than 5 years, and one important potential cause of late
excess mortality among these survivors is treatment-related
cardiac damage. The book contains invited presentations
given at the Second International Conference on the Long
Term Complications of Treatment of Children and
Adolescents with Cancer, which was held in Buffalo, New
York, in 1992. These presentations mainly focus on the two
most common agents to cause cardiac damage: radiation
therapy and anthracycline chemotherapy. In the introductory
chapter, Bricker stresses the problem of 'judiciously
navigating the-misty narrow channel between cardiac toxicity
and inappropriate limitations of treatment'. He maintains
that cardiac toxicity should be looked at as a continuous, not
a categorical, variable and that our aim should be to attempt
to preserve cardiac reserve rather than just prevent cardiac
damage. He stresses the number of variables that are con-
cerned in the development of anthracycline cardiac toxcity.
Some are well known, such as dose, age of the patient,
gender, coexisting mediastinal irradiation and ventricular
function before drug treatment. Others are less well recog-
nised, such as individual variations in myocardial activity of
various enzymes such as catalase, superoxide dismutase and
glutathione peroxidase. Previously unrecognised problems,
such as pretreatment iron status, selenium deficiency and
subclinical episodes of viral myocarditis, may also add to the
risk. He stresses that an optimal monitoring strategy has not
yet been found, and talks about the desirability ofdeveloping
load-free ventricular function testing, to overcome the prob-
klms associated with conventional tests such as M-mode
echocardiography, shortening fraction, MUGA scans, ECG
and stress velocity index.
Subsequent chapters in the book discuss the pathology of
radiation and anthracyclne-induced heart disease. Fajardo
concludes that radiation should not be viewed an an indepen-
dent cause ofcoronary artery disease, but as a co-factor with
the agents already known to be associated with this disease,
sine there is no difference in the pathology ofarterial lesions
caused by radiation and those produced by spontaneous
atherosclerosis. Adriamycin does aggravate radiation injury
through a final common end point of diffuse myocrdial
fibrosis, but, whereas for radiation this fibrosis is produced
by endotheial damage, for adriamycin there is direct toxic
effect on myocytes which are then replaced by fibrotic tissue.
The changes produced by adriamycin have been elucidated
by endomyocardial biopsy, which has made it possible to
detect early changes.
After papers disussing the pathology and pathophysiology
of anthracycline cardiac toxicity, the epidemiology of
radiation-related heart disease based on data from Stanford
University is discussed by Hancock and Donaldson, who
have identified 12 heart disease deaths in their group of 635
children and adolescents treated.
The second part of the book is devoted to papers on ways
of monitoring anthracycie therapy in the short and long
term, with regard to the factors summarised by Bricker in his
introduction. Ewer and Benjamin discuss possible ways of
preventing cardiac dam by modifying the way the drug is
given, and Berg and collagues discuss the use of cardiac
protectant agents such as ICRF 187 in modifying the toxicity
of adriamycin.
The final chapter addresses the role of genetic counselling
and the ways in which progress i genetics may make it
possible to identify individuals with significntly icreased
risks of developing late complications of cancer treatment.
The papers are clearly and coherently written and provide
an excellent overview of the subject of cardiac toxicity. It is
an important summary of the current situation both for
clinicians caring for children receiving cardiotoxic therapy
and for those concered with developing new strategies to
minimise problems in the future.
A. Barrett
1e a & Ly_phoma Reviews 2
Edited by A. Polliack, Chur, Switzerland: Harwood
Academic Publishers, 1993, 297pp. £48.00.
This book represents the second in a series of books, the
contents of which have been derived from review articles
published in the journal Leukemia and Lymphoma. This
relatively new journal has rapidly become established as an
important vehicle for publications in haematological onco-
logy. The authors have gathered reviews from volumes 5, 6